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Gender hormones and the progression of experimental poly-
cystic kidney disease.
Background. Male gender is a risk factor for progression of
autosomal-dominant polycystic kidney disease (ADPKD), clin-
ically and in the Han:SPRD rat model. Orchiectomy limits pro-
gression, but mechanisms of the detrimental effect of androgen,
and/or beneficial effects of estrogen, are not known. This pro-
tocol tested the hypothesis that male gender (intact androgen
status) promotes progression, while female gender (intact es-
trogen status) is protective; and that these disease-modifying
effects are due to changes in expression of known fibrotic
mediators.
Methods. Studies were performed in male and female noncys-
tic control (+/+) and cystic (+/−) rats subjected to orchiectomy,
ovariectomy, or sham operation. At 12 weeks of age, renal func-
tion was measured. Blood and kidneys were taken for measure-
ment of plasma and renal renin, endothelin (ET-1), endothelial
nitric oxide synthase (eNOS), and vascular endothelial growth
factor (VEGF), using biochemical, protein expression, and im-
munohistochemical methods.
Results. Cystic male rats exhibited significantly reduced
glomerular filtration (GFR) and effective renal plasma flow
(ERPF) rates, with suppression of plasma and renal renin, up-
regulation of renal ET-1 and eNOS, and down-regulation of re-
nal VEGF expression. Orchiectomy attenuated the fall in GFR
and ERPF, while numerically limiting changes in eNOS and
VEGF. Female rats exhibited less cystic growth, with normal
renin status, lesser elevation of renal ET-1, and proportionately
lesser changes in VEGF and eNOS. Ovariectomy led to higher
blood pressure and reduced GFR and ERPF, with a trend to-
ward upregulation of ET-1, and significant down-regulation of
VEGF and eNOS.
Conclusion. Female gender is protective, but ovariectomy at-
tenuates the protective effect of female gender, in association
with changes in renal expression of ET-1, VEGF, and eNOS.
The accelerated disease in male rats can be attenuated by or-
chiectomy and consequent changes in expression of disease
mediators.
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Gender is a determinant of progression of many
forms of renal disease, with males exhibiting faster
rates of progression to end-stage renal disease (ESRD).
In autosomal-dominant polycystic kidney disease
(ADPKD), recognized progression risk factors include
diagnosis younger than age 30, gross hematuria at a
young age, presence of the ADPKD1 gene, increased
renal size, hypertension, and male gender [1, 2]. Affected
men experience faster loss of renal function, and earlier
onset of ESRD, than do women [1–7]. Experimentally,
the Han:SPRD rat model shows similar gender dimor-
phism, in that females develop renal lesions only late in
life [8–12]. Orchiectomy limits renal disease (assessed by
renal size and cyst volume density), while testosterone
replacement obviates the protective effect of gonadal
ablation [10]. In females, testosterone increases kidney
and cyst growth, with or without ovariectomy [10].
Together with the recent advances in understanding of
the biology of sex hormones, these observations provide
the rationale for study of mechanisms by which these
hormones may affect the rate of progression.
These studies were designed to test several hypothe-
ses related to sex hormones and the progression of cys-
tic disease and renal insufficiency, in the Han:SPRD rat
model of ADPKD. The foregoing observations suggested
that the presence of male sex hormones (e.g., androgens),
and/or deficiency of female sex hormones (e.g., estrogen),
are associated with faster disease progression. A number
of recent reports, primarily from in vitro studies, have in-
dicated that 17b-estradiol and some of its endogenous
metabolites exert potentially protective effects on the
production, expression, and activity of various fibrotic
mediators [13]. Though less well studied, androgens may
exert specific deleterious effects. In this study, we sought
to characterize the effects of gender and of gonadal ab-
lation on the course of experimental PKD, and on the
renal expression of potentially relevant disease media-
tors. This protocol tested the overall hypothesis that male
gender (intact androgen status) promotes the progression
of disease, while female gender (intact estrogen status) is
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protective; and that this disease modification relates to al-
tered expression or activity of known mediators of growth
and fibrosis.
METHODS
These studies were conducted in Han:SPRD rats, from
a colony propagated from breeding pairs kindly provided
by Dr. Benjamin D. Cowley, Jr. (then at the Univer-
sity of Kansas Medical Center, Kansas City, KS, USA).
Heterozygous cystic rats (Cy/+) and unaffected litter-
mate control rats (+/+) were studied. All rats were
fed standard rat chow (Rodent Laboratory Chow 5001)
(Purina Mills, Richmond, IN, USA) ad libitum and had
free access to water. These studies were approved by the
Portland Veterans Affairs Institutional Animal Care and
Use Subcommittee.
Male and female control [noncystic (+/+)] and het-
erozygous (Cy/+) rats were raised to the age of 6 weeks,
at which time they underwent baseline measurements
of body weight, awake systolic blood pressure, and 24-
hour urine collections for measurement of proteinuria
(UprotV) and urinary nitrite + nitrate excretion (UNOxV).
Cystic males and females were then randomized to un-
dergo orchiectomy or ovariectomy, or sham operation.
They were then followed to the age of 12 weeks, at
which time systemic measurements were repeated, and
then some rats underwent renal function studies. In the
remainder, after anesthesia with Brevital (50 mg/kg in-
traperitoneally), kidneys were removed for morphologic
examination, protein expression studies, and immunohis-
tochemical studies as detailed below. Blood was taken for
measurement of plasma renin concentration (PRC), and
kidneys were taken for measurements of renal content
of renin (RRC) and endothelin-1 (ET-1). Other protein
and immunohistochemical measurements are described
below.
Renal function studies
Rats were anesthetized with Inactin (100 mg/kg in-
traperitoneally) and placed on a thermoregulated ta-
ble. The left femoral artery was cannulated, and a base-
line sample of blood was collected for determination of
hematocrit and inulin and paraaminohippuriate (PAH)
blanks. This arterial catheter was used for subsequent
blood sampling and for estimation of mean arterial pres-
sure (MAP) via an electronic transducer connected to a
direct writing recorder. After tracheostomy, bilateral in-
ternal jugular catheters were inserted for infusions of rat
serum and 10% inulin (Questcor, Carlsbad, CA, USA)
and 1.0% PAH (Merck, West Point, PA, USA) in saline
(1.2 mL/hour). To adjust for reduced renal clearances,
cystic rats were given 6% inulin with 0.6% PAH in saline.
The left ureter was catheterized for urine collections. To
maintain euvolemia, rat serum was infused at 0.1 mL/min
for a total equal to 1% of the body weight, followed
by a reduction in infusion to 0.42 mL/hour, to main-
tain a constant hematocrit. After equilibration, triplicate
20-minute urine collections with midpoint blood col-
lections were made, for measurement of hematocrit,
inulin and PAH. Glomerular filtration rate (GFR) (by in-
ulin clearance), effective renal plasma flow (ERPF) (by
PAH clearance), filtration fraction (FF), and renal vas-
cular resistance (RVR) were determined using standard
formulas.
Biochemical studies
For calculation of GFR, inulin concentrations in
plasma and urine were determined by the macroan-
throne method. ERPF was determined by PAH clear-
ance, with PAH concentrations in plasma and urine de-
termined by colorimetric methodology. Plasma and renal
renin concentrations were measured by radioimmunoas-
say using commercially available reagents (NEN Life Sci-
ences, Boston, MA, USA). Tissue renin concentrations
were expressed per mg protein, measured by BCA assay
(Pierce Chemical Co., Rockford, IL, USA). Urine pro-
tein was measured by precipitation with 3% sulfosalicylic
acid (Sigma Chemical Co., St. Louis, MO, USA). Renal
ET-1 was determined via an enzyme-linked immunosor-
bent assay (ELISA) method adapted from Moreau et al
[14] (Cayman Chemical, Ann Arbor, MI, USA). Urine
NOx was measured with a colorimetric assay (Cayman
Chemical Co.).
Immunoblotting
Kidneys were homogenized in one of two buffers. For
analysis of vascular endothelial growth factor (VEGF),
total cell homogenates were generated in solubilization
buffer [50 mmol/L Tris, 150 mmol/L NaCl, 0.5% sodium
deoxycholate, 0.1% sodium dodecyl sulfate (SDS),
1.0% Triton-X 100, and protease inhibitors (leupeptin,
20 lg/mL and benzamidine, 20 lg/mL)]. These ho-
mogenates were centrifuged at 12,000 × g for 30 minutes
at 4◦C and the supernatants were collected. For analy-
sis of endothelial nitric oxide synthase (eNOS), cytoso-
lic and crude-membrane preparations were generated in
lysis buffer [25 mmol/L Tris, 5 mmol/L ethylenedi-
aminetetraacetic acid (EDTA), and protease inhibitors].
These preparations were centrifuged at 100,000 × g for
60 minutes at 4◦C to obtain soluble (supernatant) and
crude-membrane (pellet) fractions. Total protein content
in fractions was determined by BCA analysis (Pierce
Chemical Co.).
Immunoblotting was performed on each preparation
as previously described [15]. In brief, denatured pro-
teins were separated through an SDS-polyacrylamide
gel and transferred to polyvinylidine difluoride (PVDF)
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membranes (Bio-Rad Laboratories, Hercules, CA,
USA). Membranes were washed and blocked overnight
with Tris-buffered saline, 0.05% Tween-20 (TBST), con-
taining 5% nonfat dry milk. Following blocking, mem-
branes were again washed, and incubated overnight with
a rabbit polyclonal antihuman VEGF antisera (A-20,
SC-152) (Santa Cruz Biotechnology Inc., Santa Cruz,
CA, USA) (1:400) or with a mouse monoclonal anti-
eNOS/NOS III antibody (#610296) (BD Transduction
Laboratories, San Diego, CA, USA) (1:1000) diluted in
TBST. Immunodetection was accomplished by incubat-
ing membranes with a goat antirabbit-IgG secondary an-
tibodies conjugated with horseradish peroxidase (HRP)
for 45 minutes (Pierce Chemical Co.) (1:100,000) in TBST
containing 5% nonfat dry milk. Visualization was per-
formed with enhanced chemiluminiscence (ECL) West-
ern blotting kit (Supersignal West Dura) (Pierce Chem-
ical Co.) according to the manufacturer’s instructions.
Resultant films (Eastman Kodak Co., Scientific Imaging
Systems, New Haven, CT, USA) were scanned using a
flatbed scanner and images analyzed with National Insti-
tutes of Health (NIH) Image software. The membranes
were then stripped, reblocked, and reincubated for 1 hour
at room temperature with goat antiactin antibody (Santa
Cruz Biotechnology) (1:200), followed by 45-minute in-
cubation with antigoat-IgG secondary antibody conju-
gated with HRP (1:4000) (Santa Cruz Biotechnology),
and reaction with ECL as described above.
Immunohistochemistry
The same antisera as described above were used for im-
munohistochemical detection of VEGF and eNOS. Sec-
tions were deparaffinized in xylene, rehydrated through
graded ethanols to water, and pretreated by steaming in
10% Citra buffer (BioGenex Laboratories, San Ramon,
CA, USA). After being treated with protein-blocking so-
lution, the slides were incubated overnight at 4◦C with
primary antibody (diluted 1:400 for VEGF and 1:1000
for eNOS) or with the same concentration of nonim-
mune IgG as a control. Endogenous peroxidase activ-
ity was blocked with 3% H2O2 solution in methanol.
The primary antibody was localized using the Vectastain
ABC-Elite peroxidase detection system (Vector Labora-
tories, Burlingame, CA, USA). This was followed by re-
action with diaminobenzidine (DAB) as chromogen and
counterstaining with hematoxylin (Sigma Chemical Co.).
Sections of each polycystic kidney were processed in par-
allel with appropriate control tissue.
Morphologic studies
The left kidneys were immersed in 10% formalin, then
dehydrated through a series of ethanols, embedded in
paraffin, sectioned at 4 lm thickness, and placed onto
glass slides. Cyst burden was quantified by a point count-
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Fig. 1. Body weights in male and female control and cystic rats, with
or without gonadectomy [orchiectomy (Orch) or ovariectomy (OVX)].
Males were heavier than females at both time points (P < 0.01). Body
weights increased in all groups (P < 0.01 vs. 6 weeks of age). The cystic
phenotype did not affect body weight. Orchiectomy had no effect on
body weight in male rats, but ovariectomy significantly increased body
weight gain in female rats (P < 0.01 vs. other female groups). ∗ P < 0.01
vs. other female groups.
ing method [16], on periodic acid-Schiff (PAS)–stained
sections.
Statistics
Values are reported as mean ± SEM. Statistical anal-
ysis was performed by paired t test, or by analysis of
variance (ANOVA) followed by computation of modi-
fied t values according to the method of Bonferroni (for
multiple groups), as appropriate. Values which were not
normally distributed were analyzed by nonparametric
methods. Statistical significance was defined as P < 0.05.
RESULTS
Changes in body weight are depicted in Figure 1. Males
were heavier than females at all time points, but the cys-
tic state did not affect somatic growth in either gender. In
cystic males, orchiectomy had no effect on body weight
gain while in cystic females, ovariectomy resulted in accel-
erated weight gain (P < 0.01 vs. other female groups). Val-
ues for systolic blood pressure were similar in all groups
at 6 weeks of age, except for a slight increment in cystic
males as compared with noncystic control rats (Fig. 2).
By 12 weeks of age, systolic blood pressure tended to be
higher in cystic than in noncystic groups, but the differ-
ences were not statistically significant. Gonadal ablation
did not affect systolic blood pressure in males, but signif-
icantly increased systolic blood pressure in cystic females
at 12 weeks (P < 0.05). Results of proteinuria studies are
shown in Figure 3. Values were low in all groups at 6 weeks
of age, and did not differ with cystic phenotype, though
baseline levels were higher in males than in females in all
groups (P < 0.05). By 12 weeks of age, proteinuria had
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Fig. 2. Systolic blood pressures (SBP) in male and female control and
cystic rats, with or without gonadectomy. Values for systolic blood pres-
sure were similar in all groups at 6 weeks of age, except slightly higher in
cystic than control males (P < 0.05). By 12 weeks of age, systolic blood
pressure was numerically but not statistically higher in both male and
female cystic rats, and systolic blood pressure rose significantly in cystic
ovariectomy females (P < 0.01). ∗P < 0.05 vs. control males; †P < 0.05,
Cys/ovariectomy, 12 weeks of age vs. baseline.
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Fig. 3. Urinary protein excretion (UprotV) in male and female control
and cystic (Cys) rats, with or without gonadectomy [orchiectomy (Orch)
and ovariectomy (OVX)]. Values for UprotV were low in all groups at
6 weeks of age, and significantly lower in females than in the corre-
sponding males (P < 0.05). By 12 weeks of age, UprotV had increased
significantly in male control (P < 0.05) and cystic (P < 0.005) rats, and
orchiectomy did not attenuate the rise in proteinuria. Values in all fe-
male groups remained comparable, and lower than those in the male
groups (P < 0.05). ∗P < 0.01 vs. baseline; †P < 0.05 vs. control males.
increased significantly in male control rats, but more so in
male cystic rats, with or without orchiectomy. Proteinuria
levels stayed low and near baseline in all female groups,
with no significant change over time, though there was a
trend toward increasing proteinuria in the ovariectomy
females.
Results of somatic and renal growth and renal hemody-
namic studies at 12 weeks of age are depicted in Table 1.
As compared with noncystic control rats, the intact male
cystic rats had comparable body weights at the time of
experimentation, but markedly enlarged kidney weights
and thus kidney body weight ratios (P < 0.01). As in our
prior studies [16–18], the cystic males also exhibited mod-
est elevations in MAP and decreased GFR and ERPF
rates (P < 0.05), a trend toward elevation in FF, and in-
creased values for renal vascular resistance (RVR) (P <
0.05 vs. controls). Orchiectomy did not affect body or kid-
ney weight, but was associated with elevation of MAP as
compared with the other male groups (P < 0.05). The or-
chiectomized male rats exhibited partially preservation
of GFR and ERPF, both in absolute terms and when
factored for body weight, as compared with intact cys-
tic males (P < 0.05). Thus, orchiectomy was associated
with preservation of renal function, despite a modest in-
crement in blood pressure.
As compared with the corresponding males, the female
control (noncystic) rats were smaller, with smaller kidney
weights but comparable kidney body weight ratios. The
female rats had lower GFR and ERPF rates than males
(P < 0.01), although the differences were eliminated
when factored for the lower body weights. Changes as-
sociated with cystic status were far less striking in the
female than in the male rats. Cystic females had renal en-
largement, but of significantly lesser magnitude than that
in cystic males (P < 0.01). In contrast to the males, the
cystic females had no impairment in GFR or ERPF, nor
increment in RVR. Thus, cystic females rats exhibited
protection against the structural and functional expres-
sion of the disease at this time point. However, functional
and structural protection was abrogated with ovariec-
tomy. The cystic kidneys in ovariectomized rats were 40%
larger than those in intact female cystic rats (P < 0.01),
though not statistically larger when factored for the dif-
ference in body weight. Functionally, when factored for
body weight, ovariectomy led to a significant reduction
in GFR and ERPF (P < 0.05). Thus, ovariectomy had
the general effect of attenuating the protective effect of
female gender on renal function.
Representative photomicrographs of renal cortex and
medulla in male and female cystic rats are depicted in
Figure 4. Cysts were prominent in both compartments in
male rats, but less so in female rats. Quantitative assess-
ment of cyst burden in intact and gonadectomized rats
(Table 1) confirmed the lower cyst burden in the female
groups, but found no significant effect of gonadal ablation
on cyst burden.
Additional studies were performed to identify likely
candidate mediators for the accelerated renal disease
progression in the male rats (Fig. 5). As previously re-
ported in this model [16], values for PRC were reduced
in cystic males, as compared with noncystic controls; or-
chiectomy had no effect on PRC. In female rats, cystic
disease did not result in any significant change in PRC.
Values for RRC were slightly reduced in both intact and
orchiectomized cystic males as compared with controls.
In female rats, RRC did not differ among groups. Values
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Table 1. Systemic and renal parameters
Males Females
Cystic + Cystic +
Controls Cystic orchiectomy Controls Cystic ovariectomy
(N = 12) (N = 12) (N = 12) (N = 10) (N = 12) (N = 10)
Body weight g 374 ± 12 359 ± 6 361 ± 6 243 ± 2a 242 ± 4a 321 ± 6a,b,c
Left kidney weight g 1.48 ± 0.04 3.86 ± 0.14c 3.73 ± 0.13c 0.96 ± 0.02a 1.86 ± 0.05a,c 2.60 ± 0.11a,b,c
Left kidney weight/100 g body weight 0.40 ± 0.01 1.08 ± 0.04c 1.03 ± 0.04c 0.39 ± 0.01 0.77 ± 0.02a,c 0.81 ± 0.04b,c
Mean arterial pressure mm Hg 127 ± 6 135 ± 2c 146 ± 7b,c 119 ± 3a 131 ± 5c 128 ± 4b,c
Glomerular filtration rate mL/min 1.96 ± 0.08 0.77 ± 0.10c 1.10 ± 0.09b,c 1.30 ± 0.08a 1.31 ± 0.07a 1.44 ± 0.10a
Glomerular filtration rate/100 g body weight 0.53 ± 0.02 0.22 ± 0.03c 0.31 ± 0.03b,c 0.53 ± 0.03 0.55 ± 0.03a 0.45 ± 0.03a,b,c
Effective renal plasma flow mL/min 7.13 ± 0.31 2.63 ± 0.36c 3.59 ± 0.29b,c 4.47 ± 0.27a 4.21 ± 0.28a 4.62 ± 0.36
Effective renal plasma flow/100 g body weight 1.93 ± 0.09 0.75 ± 0.11c 1.00 ± 0.09b,c 1.84 ± 0.12 1.76 ± 0.12a 1.45 ± 0.13a,b,c
Filtration fraction 0.28 ± 0.01 0.30 ± 0.01 0.31 ± 0.02c 0.29 ± 0.01 0.32 ± 0.01c 0.32 ± 0.01a
Renal vascular resistance mm Hg/mL/min 10.6 ± 0.5 40.3 ± 6.9c 28.7 ± 3.0c 17.2 ± 1.3 20.6 ± 1.7a 18.6 ± 2.0
Cyst burden% – 20.3 ± 2.4 17.0 ± 0.9 – 6.6 ± 0.4a 7.9 ± 0.5a
Values are mean ± SEM.
aP < 0.05, female vs. respective male group; bP < 0.05 vs. respective intact group; cP < 0.05 vs. respective noncystic control.
Cortex Medulla
Male
Female
Fig. 4. Representative photomicrographs of renal cortex and medulla
in male and female, cystic and noncystic rats. Cystic changes were ap-
parent in both compartments in male rats, but were less prominent in
female rats [40× periodic acid-Schiff (PAS) stain].
for renal ET-1 were markedly elevated in cystic male rats
(P < 0.01), and unaffected by orchiectomy. In cystic fe-
male rats, renal ET-1 levels were significantly increased
as compared with noncystic controls (P < 0.05), though
not to levels seen in cystic males. Ovariectomy was asso-
ciated with a trend toward further increased renal ET-1
values, to levels near those seen in cystic male groups.
Protein expression and immunohistochemical localiza-
tion studies were used to examine renal expression of
VEGF. Normalized VEGF protein expression was signif-
icantly reduced in cystic males, as compared with noncys-
tic males (Fig. 6A) (P < 0.05). Noncystic female control
rats demonstrated up-regulation of VEGF expression, as
compared with noncystic males, whereas expression was
also reduced in cystic females (P < 0.05). Orchiectomy
slightly, though not significantly, increased VEGF expres-
sion in cystic males (Fig. 6B). In females, ovariectomy re-
sulted in a further reduction in VEGF expression (P <
0.05). Immunohistochemical studies in noncystic control
males revealed that VEGF expression was detected pri-
marily in the thick ascending limb and distal tubular cells,
in glomerular epithelial cells, and in vascular endothelia
(Fig. 7). In the cystic male rats, VEGF was found mostly
in cystic epithelial cells, and in atrophic tubules. Qualita-
tively, expression was similar in the males and females.
Renal expression of eNOS was also examined. As com-
pared with noncystic males, renal eNOS was increased in
male cystic kidneys (P < 0.05), and not significantly af-
fected by orchiectomy (Fig. 8). Renal eNOS expression
in noncystic females was higher than that in the respec-
tive male group. Expression of eNOS was up-regulated in
the kidneys of cystic female rats, as compared with non-
cystic controls, but then reduced by ovariectomy. In im-
munohistochemical studies (not shown), eNOS displayed
a diffuse granular pattern in tubular cells, in both cystic
and noncystic rats. Immunoreactivity was also clearly de-
tectable in arterial and arteriolar endothelial cells and to
a lesser extent, in endothelia of glomerular capillaries, as
previously reported [18]. Immunohistochemical analysis
did not provide qualitative differences between the cys-
tic and control groups, nor between the various groups.
In addition, measurements of UNOxV did not show any
consistent differences among groups (data not shown).
DISCUSSION
Gender as a risk factor
Male gender has recently been recognized as a risk fac-
tor for acceleration of clinical renal disease, especially in
nondiabetic forms of chronic kidney disease. Men with
ADKPD exhibit faster rates of progression and earlier
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Fig. 5. Plasma renin concentration (PRC), renal renin concentration
(RRC), and renal endothelin-1 (ET-1). PRC and RRC were suppressed
in the cystic male groups, but not in the cystic female groups. Renal
ET-1 expression was up-regulated in cystic males, and not affected by
orchiectomy. In females, the degree of up-regulation associated with the
cystic state was lesser than in males, and was attenuated by ovariectomy.
∗P < 0.01 vs. respective control; †P < 0.05 vs. respective male group.
onset of ESRD than do affected women [1–7, 19–21]. Sim-
ilar gender dimorphism has been noted in the Han:SPRD
[8–12] and pck [22] rat PKD models; data in mouse mod-
els are less clear. The present studies confirm prior obser-
vations of gender dimorphism in progression of experi-
mental PKD. As others have shown [8–12], female rats
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Fig. 6. Representative Western blots of vascular endothelial growth
factor (VEGF) and actin in male and female, cystic and noncystic rats.
(A) The VEGF/actin ratio was reduced in male cystic (MCys) rats,
as compared with noncystic controls (MC). Noncystic females (FC)
demonstrated higher expression than noncystic males, but the cystic
phenotype (FCys) was also associated with reduction in VEGF expres-
sion in female rats. ∗P < 0.05 vs. control males; †P < 0.01 vs. control
females. (B) Orchiectomy (Orch) led to a slight but not significant in-
crease in VEGF; ovariectomy (OVX) significantly reduced renal VEGF
expression. ∗P < 0.05 vs. respective controls; †P < 0.01 vs. cystic females.
are relatively protected against expression of the disease
phenotype, with smaller kidneys, a lower cyst burden, and
relative preservation of renal function. Though not yet
studied in a PKD model, administration of exogenous
estradiol has been reported to have renoprotective effects
in experimental models of diabetes [23], aging [24], renal
ablation [25], and chronic allograft nephropathy [26].
Renal function and cyst burden: Males
Prior gender studies assessed renal function with rel-
atively insensitive methodologies (e.g., serum creatinine
or creatinine clearance). As previously reported [16–18],
more precise clearance measurements indicate intense
renal vasoconstriction in the male rats, with decreased
values for ERPF, and elevation of FF and RVR. These
results correspond with clinical reports of low ERPF,
high RVR, and elevation of FF [27–32], as well as severe
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Anti-VEGF antibody Non-immune serum
Fig. 7. Representative immunohistochemical expression of vascular
endothelial growth factor (VEGF) in male and female, cystic and non-
cystic rats. Left panels show sections stained with anti-VEGF antibody.
Right panels show parallel control sections incubated with nonimmune
serum. In noncystic male and female kidneys, the VEGF was found
predominantly in distal tubules (green arrows), glomerular epithelial
cells (black arrows), and in some arterial or arteriolar endothelia (red
arrows). In both male and female cystic rats, renal VEGF immunore-
activity was found mainly in epithelial cells lining the cyst walls as well
in atrophic tubuli (blue arrows). There were no apparent differences
between male and female rats.
sclerosis of the preglomerular vessels [33]. More re-
cently, magnetic resonance measurements have con-
firmed strong concordance between reductions in renal
blood flow and disease severity in patients with ADPKD
[34]. Furthermore, renal blood flow declines earlier than
GFR, and predicts structural and functional progression
in clinical ADPKD [abstract; Torres V, et al, J Am Soc
Nephrol 15:13A, 2004].
The gonadal ablation studies provided further evi-
dence for a role of gender and/or related hormones in
the modulation of renal hemodynamics. The renal vaso-
constriction in male cystic rats was attenuated by orchiec-
tomy, suggesting that intact androgen status contributes
to renal insufficiency. Our inability to detect a favorable
effect of orchiectomy on cyst burden was likely related to
the relatively short period of observation, as well as to the
relatively late age at which the gonadal ablation was per-
formed. Cystic changes in this model are expressed very
early in life, with significant increases in renal size seen
in the first few weeks of life. At the time of orchiectomy,
cystic changes were already in progress, and therefore
effects of short-term intervention on kidney weight and
cyst burden were likely more difficult to detect.
The equivalent values for GFR and ERPF (normal-
ized for body weight) in the intact, noncystic male and
female groups suggest a minimal influence of sex hor-
mones on baseline renal function. Gender hormones
have not been extensively studied in this model. Serum
testosterone levels are low in cystic male rats [35], while
there is increased renal expression of the androgen re-
ceptor, as compared with noncystic males [36]. However,
the higher androgen receptor levels were located the
cystic epithelium, where a role in modulation of renal
blood flow would likely be indirect at best, and serum
testosterone levels have not been well correlated with
intrarenal events. Another abstract noted that adminis-
tration of the androgen receptor antagonist flutamide was
associated with slowing of cyst development, associated
with suppression of elevated serum creatinine activity
[36]. In addition, male cystic kidneys exhibit higher levels
of macrophage chemoattractant protein-1 (MCP-1) than
do female cystic kidneys [37]. It has also been suggested
that androgens may contribute to apoptosis and thereby
influence progression [38], but this pathway has not been
well explored in vivo. Though not well studied in re-
nal disease, androgens have the potential for interaction
with important endogenous vasoactive mediators which
may have contributed to the apparent negative effects
(see below).
Renal function and cyst burden: Females
With the clearance methods in the present study, we are
able to demonstrate preservation of normal renal func-
tion in the female cystic rats. In concert with the lower
cyst burden, cystic females exhibited essentially normal
values for GFR and ERPF. However, when factored for
body weight, both GFR and ERPF fell after ovariectomy,
suggesting that endogenous levels of estrogen and/or re-
lated female hormones contributed to protection against
the development of renal vasoconstriction in this model.
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noncystic rats. (C) The eNOS/actin ratio was
increased in male cystic rats, as compared with
noncystic controls, and not affected by or-
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was associated with further up-regulation of
eNOS, but this up-regulation was limited by
ovariectomy (OVX). MW is molecular weight
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positive control. ∗P < 0.001 vs. respective non-
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There is substantial evidence that estrogen plays a role
in modulation of vascular function, in the kidney as well
as in the systemic circulation. As is further discussed be-
low, estrogens interact with a number of endogenous va-
soactive mediators which may contribute to its appar-
ent beneficial effects. In the Han:SPRD model, we found
that intact, noncystic females had GFR and ERPF values
(relative to body weight) that did not differ from those
in males, so baseline (strain) differences did not play a
role. Only when the cystic state was superimposed did
the gender difference become expressed. On the other
hand, ovariectomy produced a detrimental effect in cystic
females, suggesting a protective role for estrogen and/or
related hormones.
Role of the renin-angiotensin system (RAS)
These studies further examined activity of several va-
soactive disease mediators, which may explain some of
the sex hormone–associated differences. Prior studies
have suggested that inappropriate or elevated activity of
the RAS may be involved in regulation of renal func-
tion and cyst progression in ADPKD. Renal parenchymal
ischemia, resulting from compression induced by cystic
enlargement, has been postulated to stimulate the RAS.
Studies in ADPKD patients have noted hyperplasia of
the juxtaglomerular apparatus, and redistribution and ex-
pansion of renin immunoreactivity into blood vessels and
the tubulointerstitium [39, 40], as well as in the cyst fluid
[39]. Furthermore, angiotensin II (Ang II) formation in-
dependent from angiotensin converting enzyme (ACE)
is suggested by the finding of increased chymase-like Ang
II–generating capacity in human ADPKD kidneys [41].
Ectopic renin expression is postulated to contribute to
increased renal Ang II production. Indeed, all RAS com-
ponents are found in the cyst apparatus, suggesting the
possibility of an autocrine/paracrine RAS in the cystic
kidney [42]. In further support of the hypothesis of in-
trarenal RAS activation are observations of low PRC
(presumably suppressed by intrarenal RAS activation),
and exaggerated renal vascular responsiveness to RAS
blockade [16].
In the present studies, we again found suppression of
PRC in the cystic male rats; orchiectomy had no apparent
effect. RRC was also suppressed in cystic males. Though
not well studied, androgens if anything serve to stimulate
the RAS [43], but we could not confirm that postulate
with the present study design. The low RRC values in
cystic males may be a consequence of progressive loss
or destruction of the juxtaglomerular apparatus due to
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cyst formation. Furthermore, suppression of RRC could
be a consequence of higher intrarenal Ang II levels, but
without localization data, no further conclusions can be
drawn. In the female rats, PRC and RRC in intact noncys-
tic females did not differ from values in noncystic males.
In contrast to the males, there was no apparent effect
of the cystic state on either parameter, nor any effect
of ovariectomy. The relationship between estrogen and
the RAS is complex. Estradiol increases angiotensinogen,
while suppressing renin, ACE, aldosterone, and the an-
giotensin type 1 (AT1) receptor [44–48], and up-regulates
the AT2 receptor [48]. On the other hand, some estrogen
preparations such as those in oral contraceptives have
been reported to stimulate the RAS [49]. Future studies
will be required to dissect the interaction between estro-
gen and the RAS in this model.
Role of ET-1
The RAS in turn interacts with many other mediators,
which are also influenced by sex hormones. ET-1 is a
potent vasoconstrictor which is implicated in the patho-
physiology of cyst formation and renal dysfunction in this
model [18, 50]. Plasma ET-1 levels are high in ADPKD
patients [51, 52], and ET-1 is present in human cyst fluid
[51]. Serum ET-1 levels are higher in men than in women
[53], and estrogen therapy [such as hormone replacement
therapy (HRT)] reduces ET-1 levels [54]. Furthermore,
estradiol inhibits basal and Ang II–induced ET-1 synthe-
sis in vascular endothelial cells [55]. As in prior studies
[18], we again found marked elevation of renal ET-1 lev-
els in kidneys from cystic males; orchiectomy was with-
out effect. There were no significant differences between
male and female noncystic kidneys. Cystic female kidneys
exhibited increased expression of ET-1, though not to the
degree seen in males, suggesting a modulatory effect of
gender. When this modulatory effect of gender was abro-
gated by ovariectomy, renal ET-1 levels rose toward levels
near those seen in cystic males. Thus, ET-1 appears to be
a significant disease mediator; recent evidence suggests
that ET-1 is detrimental via the ETB receptor [56]. Limi-
tation of ET-1 in female rats (presumably at least in part
by estrogen) may contribute to the amelioration of renal
vasoconstriction, as well as to the lesser development of
cystic injury.
Role of nitric oxide
The RAS, ET-1, and sex hormones also interact with
nitric oxide. Estradiol is a potent stimulus for formation
of eNOS and subsequent generation of nitric oxide [57].
Clinically, HRT increases nitric oxide, suppresses ET-1,
and thus increases the nitric oxide/ET ratio [54]. Female
rats exhibit higher endogenous renal eNOS mRNA and
protein, and lesser vasoconstriction in response to NOS
inhibition [58], while male rats are more prone to pro-
teinuria after NOS blockade [59]. Effects of androgens
on nitric oxide in the kidney are less well studied, though
testosterone has variable effects on vascular reactivity in
different experimental systems.
We reported earlier that in renal eNOS was up-
regulated, in male cystic rats, but primarily in extravas-
cular structures [18]. Our data were consistent with the
scenario of exaggerated hemodynamic actions of Ang
II due to both loss of buffering by a dysfunctional ni-
tric oxide system, and by concomitant activation of the
ET system. With regard to eNOS expression, we again
found evidence of up-regulation in cystic male kidneys,
as compared with noncystic males. Orchiectomy had only
a slight effect on renal eNOS expression. As compared
with males, however, eNOS levels were comparably up-
regulated in cystic females, but then reduced by ovariec-
tomy, suggesting that eNOS is at least in part regulated by
estrogen in the cystic kidney. It should be also noted that
determination of sole eNOS protein expression does not
fully reflect its enzymatic activity and resulting protec-
tive potential of eNOS-derived nitric oxide. The present
findings should prompt future studies in PKD focusing
on functional characteristics of eNOS, such as phospho-
rylation and coupling-uncoupling status.
Role of VEGF
All of the above hormones and mediators also in-
teract with VEGF, a mediator with a complex role
in the kidney [60]. Estrogen is a potent stimulator of
VEGF and angiogenesis [61]. Little is known of VEGF
in PKD, though it has been postulated that ischemia
from cyst compression, and resultant hypoxia, might
represent local stimuli for VEGF expression. Bello-
Reuss et al [62] found up-regulation of VEGF in the
vicinity of the cysts in human ADPKD kidneys, and
postulated that angiogenesis and enhanced capillary
formation support the perpetuation of cyst growth. Re-
cent abstracts have noted increased renal expression of
the angiogenic isoforms of VEGF [abstract; Tao Y et al,
J Am Soc Nephrol 14:582A, 2004], and high levels of
VEGF (by ELISA) in kidneys and in cyst fluid of
Han:SPRD rats, with reduction of cyst volume density
after combined VEGFR1 and 2 blockade [abstract; Tao
Y et al, J Am Soc Nephrol 15:656A, 2004]. While there
is evidence of a detrimental effect of VEGF in glomeru-
lar pathophysiology and possibly cyst growth, its role in
preservation of the tubulointerstitium appears to be more
positive. Kang et al [63, 64] have demonstrated an asso-
ciation between VEGF deficiency and peritubular cap-
illary loss and development of fibrosis in renal disease
models. In studies of the remnant kidney, these investi-
gators demonstrated relative VEGF deficiency in male
kidneys, exacerbated by the superimposition of reduced
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renal mass [64]. Those findings are in complete accord
with our observations of down-regulation of VEGF in
kidneys of cystic males, as compared with cystic females.
A role for androgens is suggested by downregulation of
VEGF in kidneys of noncystic males, as compared with
females, and with exaggerated suppression of VEGF in
cystic males, as compared with cystic females. On the
other hand, ovariectomy was associated with reduction
in VEGF in cystic female kidneys. Taken together, these
data are suggestive of a protective role of VEGF (and of
estrogen-associated VEGF expression) in the cystic kid-
ney. Further studies, designed to examine the peritubular
capillaries, would be of interest in this regard.
The present findings expand upon prior observations
of gender dimorphism in this model, and suggest a promi-
nent role for gender hormones. We speculate that in the
males, the presence of intact androgen status is asso-
ciated with stimulation of the RAS and ET-1 systems.
Down-regulation of VEGF and possibly bioavailable ni-
tric oxide further contribute to vasoconstriction and pro-
gression of cystic and fibrotic disease components. In the
females, estrogen has a protective effect, inducing sup-
pression of the intrarenal RAS and ET-1 systems, and
up-regulation of VEGF, thereby promoting preservation
of renal function and attenuation of the loss of structure.
The estrogen effect may be more dominant than the an-
drogen effect. Further studies of specific gender hormone
modulation will be of interest, in search of clinically appli-
cable approaches to slowing the progression of ADPKD.
ACKNOWLEDGMENTS
These studies were supported by a grant from the Polycystic Kidney
Research Foundation. We are grateful to William E. Schutzer, M.S., and
Douglas Beard, B.S., for additional expert technical assistance. Portions
of these studies have been published in abstract form (J Am Soc Nephrol
145:658A, 2004)
Reprint requests to Sharon Anderson, M.D., Division of Nephrology
and Hypertension, PP262 Oregon Health and Science University, 3314
SW US Veterans Hospital Rd., Portland, OR 97239-2940.
E-mail: anderssh@ohsu.edu
REFERENCES
1. GABOW PA, JOHNSON AM, KAEHNY WD: Factors affecting the pro-
gression of renal disease in autosomal dominant polycystic kidney
disease. Kidney Int 41:1311–1319, 1992
2. JOHNSON AM, GABOW PA: Identification of patients with autosomal
dominant polycystic kidney disease at highest risk for end-stage
renal disease. J Am Soc Nephrol 8:1560–1567, 1997
3. MODIFICATION OF DIET IN RENAL DISEASE STUDY GROUP: Dietary
protein restriction, blood pressure control, and the progression of
polycystic kidney disease. J Am Soc Nephrol 5:2037–2047, 1995
4. STEWART JH: End-stage renal failure appears earlier in men than in
women with polycystic kidney disease. Am J Kidney Dis 24:181–183,
1994
5. FICK-BROSNAHAN GM, BELZ MM, MCFANN KK, et al: Relationship
between renal volume growth and renal function in autosomal dom-
inant polycystic kidney disease: A longitudinal study. Am J Kidney
Dis 39:1127–1134, 2002
6. CHAKROUN G, ITAKURA Y, ALBOUZE G, et al: Factors influencing pro-
gression of renal failure in autosomal dominant polycystic kidney
disease. J Am Soc Nephrol 6:1634–1642, 1995
7. GRETZ N, ZEIER M, GEBERTH S, et al: Is gender a determinant for
evolution of renal failure? A study in autosomal dominant polycystic
kidney disease. Am J Kidney Dis 14:178–183, 1989
8. GRETZ N, CECCHERINI I, KRA¨NZLEIN B, et al: Gender-dependent dis-
ease severity in autosomal polycystic kidney disease of rats. Kidney
Int 48:496–500, 1995
9. COWLEY BD, JR, GUDAPATY S, KRAYBILL AL, et al: Autosomal dom-
inant polycystic kidney disease in the rat. Kidney Int 43:522–534,
1993
10. COWLEY BD, JR, RUPP JC, MUESSEL MJ, GATTONE VH, II: Gender
and the effect of gonadal hormones on the progression of inherited
polycystic kidney disease in rats. Am J Kidney Dis 29:265–272, 1997
11. YOSHIDA I, BENGAL R, TORRES VE: Gender-dependent effect of L-
NAME on polycystic kidney disease in Han:SPRD rats. Am J Kid-
ney Dis 35:930–936, 2000
12. TORRES VE, BENGAL RJ, NICKANDER KK, et al: Renal concentration
of a-tocopherol: dependence on gender and lack of effect on poly-
cystic kidney disease in Han:SPRD rats. Am J Kidney Dis 31:687–
693, 1998
13. DUBEY RK, JACKSON EK: Estrogen-induced cardiorenal protection:
potential cellular, biochemical, and molecular mechanisms. Am J
Physiol 280:F365–F388, 2001
14. MOREAU P, D’USCIO LV, SHAW S, et al: Angiotensin II increases
tissue endothelin and induces vascular hypertrophy: Reversal ETA-
receptor antagonist. Circulation 86:1593–1597, 1997
15. KOMERS R, LINDSLEY JN, OYAMA TT, et al: Immunohistochemical
and functional correlations of renal cyclooxygenase-2 in experimen-
tal diabetes. J Clin Invest 197:889–898, 2001
16. KENNEFICK TM, AL-NIMRI MA, OYAMA TT, et al: Hypertension and
renal injury in experimental polycystic kidney disease. Kidney Int
56:2181–2190, 1999
17. KANG S-K, OYAMA TT, KENNEfiCK TM, et al: Impaired adaptation to
renal mass reduction in the polycystic rat. Am J Kidney Dis 35:923–
929, 2000
18. AL-NIMRI MA, KOMERS R, OYAMA TT, et al: Endothelial-derived va-
soactive mediators in polycystic kidney disease. Kidney Int 63:1176–
1784, 2003
19. NEUGARTEN J, ACHARYA A, SILBIGER SR: Effect of gender on the
progression of nondiabetic renal disease: a meta-analysis. J Am Soc
Nephrol 11:319–329, 2000
20. ISHIKAWA I, MAEDA K, NAKAI S, et al: Gender difference in the
mean age at the induction of hemodialysis in patient with autosomal
dominant polycystic kidney disease. Am J Kidney Dis 35:1072–1075,
2000
21. SILBIGER SR, NEUGARTEN J: The role of gender in the progression
of renal disease. Adv Ren Repl Ther 10:3–14, 2003
22. LAGER DJ, QIAN Q, BENGAL RJ, et al: The pck rat: A new model
that resembles human autosomal dominant polycystic kidney and
liver disease. Kidney Int 59:126–136, 2001
23. MANKHEY RW, BHATTI F, MARIC C: 17b-estradiol replacement
improves renal function and pathology associated with diabetic
nephropathy. Am J Physiol 288:F399–F405, 2005
24. MARIC C, SANDBERG K, HINOJOSA-LABORDE C: Glomerulosclerosis
and tubulointerstial fibrosis are attenuated with 17b-estradiol in the
aging Dahl salt sensitive rat. J Am Soc Nephrol 15:1546–1556, 2004
25. ANTUS B, HAMAR P, KOKENY G, et al: Estradiol is nephroprotective
in the rat remnant kidney. Nephrol Dial Transplant 18:54–61, 2003
26. ANTUS B, YAO Y, SONG E, et al: Opposite effects of testosterone and
estrogens on chronic allograft nephropathy. Transpl Int 15:494–501,
2002
27. GABOW PA, IKLE DW, HOLMES JH: Polycystic kidney disease:
Prospective analysis of non-azotemic patients and family members.
Ann Intern Med 101:238–247, 1984
28. TORRES VE, WILSON DM, OFFORD KP, et al: Natriuretic response
to volume expansion in polycystic kidney disease. Mayo Clin Proc
64:509–515, 1989
29. TORRES VE, WILSON DM, BURNETT JC: Effect of inhibition of con-
verting enzyme on renal hemodynamics and sodium management.
Mayo Clin Proc 66:1010–1017, 1991
30. BARRETT BJ, FOLEY R, MORGAN J, et al: Differences in hormonal and
Stringer et al: Gender hormones in PKD 1739
vascular responses between normotensive patients with autosomal
dominant polycystic kidney disease and unaffected family members.
Kidney Int 46:1118–1123, 1994
31. HARRAP SB, DAVIES DL, MACNICOL AM, et al: Renal, cardiovas-
cular and hormonal characteristics of young adults with autoso-
mal dominant polycystic kidney disease. Kidney Int 40:501–508,
1991
32. RAMUNNI A, SARACINO A, ESPOSITO T, et al: Renal vascular resistance
and renin-angiotensin system in the pathogenesis of early hyperten-
sion in autosomal dominant polycystic kidney disease. Hypertens
Res 27:221–225, 2004
33. ZEIER M, FEHRENBACH P, GEBERTH S, et al: Renal histology in poly-
cystic kidney disease with incipient and advanced renal failure. Kid-
ney Int 42:1259–1265, 1992
34. KING BF, TORRES VE, BRUMMER ME, et al: Magnetic resonance mea-
surements of renal blood flow as a marker of disease severity in
autosomal-dominant polycystic kidney disease. Kidney Int 64:2214–
2221, 2003
35. JAYAPALAN S, SABOORIAN MH, EDMUNDS JW, AUKEMA HM: High
dietary fat intake increases renal cystic disease progression in
Han:SPRD-cy rats. J Nutr 130:2356–60, 2000
36. NAGAO S, KUSAKA M, NISHII K, et al: Androgen receptor pathway in
rats with autosomal dominant polycystic kidney disease. J Am Soc
Nephrol 16:2052–2062, 2005
37. COWLEY BD, JR, RICARDO SD, NAGAO S, DIAMOND JR: Increased
renal expression of monocyte chemoattractant protein-1 and osteo-
pontin in ADPKD in rats. Kidney Int 60:2087–2096, 2001
38. GANDOLFO MT, VERZOLA D, SALVATORE F, et al: Gender and the
progression of chronic renal diseases: does apoptosis make the dif-
ference? Minerva Urol Nefrol 56:1–14, 2004
39. TORRES VE, DONOVAN KA, SCICLI G, et al: Synthesis of renin by
tubulocystic epithelium in autosomal-dominant polycystic kidney
disease. Kidney Int 42:364–373, 1992
40. GRAHAM PC, LINDOP GBM: The anatomy of the renin-secreting cell
in adult polycystic kidney disease. Kidney Int 33:1084–1090, 1988
41. MCPHERSON EA, LUO Z, BROWN RA, et al: Chymase-like angiotensin
II-generating activity in end-stage human autosomal dominant
polycystic kidney disease. J Am Soc Nephrol 15:493–500, 2004
42. LOGHMAN-ADHAM M, SOTO CE, INAGAMI T, CASSIS L: An intrarenal
renin-angiotensin system in autosomal dominant polycystic kidney
disease. Am J Physiol 287:F775–F788, 2004
43. CHEN Y-F, NAFTILAN AJ, OPARIL S: Androgen-dependent an-
giotensinogen and renin mRNA expression in hypertension rats.
Hypertension 19:456–463, 1992
44. SCHUNKERT H, DANSER AH, HENSE HW, et al: Effects of estrogen
replacement on the renin-angiotensin system in postmenopausal
women. Circulation 95:39–45, 1997
45. CAMPBELL DJ: Differential regulation of angiotensin peptides in
plasma and kidney: effects of adrenalectomy and estrogen treat-
ment. Clin Exp Hypertens 19:687–698, 1997
46. NICKENING G, BA¨UMER AT, GROHE` C, et al: Estrogen modulates AT1
receptor gene expression in vitro and in vivo. Circulation 97:2197–
2201, 1998
47. NICKENING G, SHREHLOW K, WASSMANN S, et al: Differential ef-
fects of estrogen and progesterone on AT1 receptor gene expres-
sion in vascular smooth muscle cells. Circulation 102:1828–1833,
2000
48. ARMANDO I, JEZOVA M, JUORIO AV, et al: Estrogen upregulates renal
angiotensin II AT2 receptors. Am J Physiol 283:F934–F043, 2002
49. KANG AK, DUNCAN JA, CATTRAN DC, et al: Effect of oral contra-
ceptives on the renin angiotensin system and renal function. Am J
Physiol 280:R807–R813, 2001
50. HOCHER B, ZART R, SCHWARZ A, et al: Renal endothelin system in
polycystic kidney disease. J Am Soc Nephrol 9:1169–1177, 1998
51. MUNEMURA C, UEMASU J, KAWASAKI H: Epidermal growth factor
and endothelin in cyst fluid from autosomal dominant polycystic
kidney disease cases: Possible evidence of heterogeneity in cystoge-
nesis. Am J Kidney Dis 24:561–568, 1994
52. GIUSTI R, NERI M, ANGELINI D, et al: Plasma concentration of en-
dothelin and arterial pressure in patients with ADPKD. Contrib
Nephrol 115:118–121, 1995
53. POLDERMAN KH, STEHOUWER CDA, VAN KAMP GJ, et al: Influence of
sex hormones on plasma endothelin levels. Ann Intern Med 118:429–
432, 1993
54. SAITTA A, ALTAVILLA D, CUCINOTTA D, et al: Randomized,
double-blind, placebo-controlled study on effects of raloxifene
and hormone replacement therapy on plasma NO concentrations,
endothelin-1 levels, and endothelium-dependent vasodilation in
postmenopausal women. Arterioscler Thromb Vasc Biol 21:1512–
1519, 2001
55. DUBEY RK, JACKSON EK, KELLER P, et al: Estradiol metabolites
inhibit endothelin synthesis by an estrogen receptor-independent
mechanism. Hypertension 37 (Pt 2):640–644, 2001
56. HOCHER B, KALK P, SLOWINSKI T, et al: ETA receptor blockade in-
duces tubular cell proliferation and cyst growth in rats with poly-
cystic kidney disease. J Am Soc Nephrol 14:367–376, 2003
57. ZHU W, SMART EJ: Caveolae, estrogen and nitric oxide. Trends En-
docrinol Metab 14:114–117, 2003
58. RECKELHOFF JF, HENNINGTON BS, MOORE AG, et al: Gender differ-
ences in the renal nitric oxide (NO) system: dissociation between
expression of endothelial NO synthase and renal hemodynamic re-
sponse to NO synthase inhibition. Am J Hypertens 11:97–104, 1998
59. VERHAGEN AM, ATTIA DM, KOOMANS HA, JOLES JA: Male gender
increases sensitivity to proteinuria induced by mild NOS inhibition
in rats: role of sex hormones. Am J Physiol 279:F664–F670, 2000
60. SCHRIJVERS BF, FLYVBJERG A, DE VRIESE AS: The role of vascular en-
dothelial growth factor (VEGF) in renal pathophysiology. Kidney
Int 65:2003–2007, 2004
61. LOSORDO DW, ISNER JM: Estrogen and angiogenesis. A review. Ar-
terioscler Thromb Vasc Biol 21:6–12, 2001
62. BELLO-REUSS E, HOLUBEC K, RAJARAMAN S: Angiogenesis in
autosomal-dominant polycystic kidney disease. Kidney Int 60:37–
45, 2001
63. KANG D-H, KANELLIS J, HUGO C, et al: Role of the microvascular
endothelium in progressive renal disease. J Am Soc Nephrol 13:806–
816, 2002
64. KANG DH, YU ES, YOON KI, JOHNSON R: The impact of gender on
progression of renal disease: potential role of estrogen-mediated
vascular endothelial growth factor regulation and vascular protec-
tion. Am J Pathol 164:679–688, 2004
